Market Overview

Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Share:
Related NAVB
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

Posted-In: News

 

Related Articles (NAVB)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→